Comparative analysis of the cost and effectiveness of generic and brand‐name antibiotics: the case of uncomplicated urinary tract infection

Abstract

Compared with those treated with brand-name antibiotics, outpatients who received generic antibiotics had equivalent treatment outcomes with lower drug costs. Generic antibiotics are effective and worthy of adoption among outpatients with simple infections indicating oral antibiotic treatment. Copyright © 2016 John Wiley & Sons, Ltd.

Results of the effectiveness of two piperacillin–tazobactam molecules in the real world

“…The safety and therapeutic equivalence of generic antibiotics is a controversial issue. However, the data from this study, along with real-world evidence, indicate that its use can be as safe and effective as the innovator, which has been demonstrated for other antimicrobials and other infections, and for different indications, such as cardiovascular (McCormack and Chmelicek, 2014;Rodriguez et al, 2016;Lin et al, 2016;Kesselheim et al, 2016;Jackevicius et al, 2016). In addition, economic analyses have shown that generic antibiotic treatments during a 5-day hospitalization cost on average US$ 45.5-98.2, while the use of innovators can cost US$ 106.2-463.7.…”

“…From these findings, it can be concluded that no statistically significant differences were found in all-cause mortality, mortality by infection, or hospital stay between patients treated with innovator piperacillin-tazobactam and those treated with generic piperacillin-tazobactam at the clinic where the study was performed. Data and evidence from the real world are an increasingly important source of reliable information about the use of drugs, in this case about antibiotics, that can support physicians and decision-makers when choosing a cost-effective option (Lin et al, 2016). Further studies are required that compare important variables of effectiveness and safety among the different groups of commercial and generic drugs that serve as a basis for rational prescription guidelines.…”

Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications

“…Low prices for PPIs are important in countries given appreciably increased utilization over the last 10 to 20 years, especially countries with universal healthcare and competing demands on available resources, with published studies showing no difference in the effectiveness and safety of generic versus originator PPIs, like other disease areas [87][88][89][90][91][92]. Low-cost multiple-sourced PPIs are also essential for patients with GERD in low-and middle-income countries (LMICs) with their high patient co-payment levels.…”

Real-World Effectiveness of Meropenem: Results of an Observational Study in 84 Colombian Patients

“…The effectiveness of different generic antimicrobials has previously been studied in different situations [8][9][10]. At a local level, there is evidence for its equivalence to innovative medications in terms of mortality, length of hospital stay and safety [11].…”